Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Treatments by Mechanism

Top 12 mechanisms across 92 industry trials with a known mechanism of action.

See full pipeline →

Androgen Receptor

10 trials 8 active 2 sponsors

Androgen Receptor Inhibitor

29 trials 3 active 8 sponsors

Kinase Inhibitor

6 trials 3 active 3 sponsors

Poly(ADP-Ribose) Polymerase Inhibitor

5 trials 3 active 1 sponsor

AXL/FLT-3/KIT/MER/MET/RET/ROS1/TIE-2/TRKB/TYRO3/VEGFR-1/VEGFR-2/VEGFR-3

5 trials 2 active 1 sponsor

AKT1/AKT2/AKT3

3 trials 2 active 1 sponsor

CYP17

12 trials 1 active 7 sponsors

Programmed Death Receptor-1 Blocking Antibody

12 trials 1 active 3 sponsors

Photoenhancer

1 trials 1 active 1 sponsor

Androgen Receptor/Progesterone Receptor

1 trials 1 active 1 sponsor

Gonadotropin Releasing Hormone Receptor Antagonist

4 trials 3 sponsors

RANK Ligand Inhibitor

4 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Clinical Pipeline by Phase

869 industry-sponsored trials across 342 sponsors

View full landscape →

Showing 31 of 31 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Bayer	Darolutamide (Nubeqa, BAY1841788)	—	RECRUITING	2027-04-29	NCT05348876
Novartis	AAA617	—	RECRUITING	2033-07-20	NCT05803941
Lantheus Medical Imaging	Piflufolastat F 18 Intravenous Solution [PYLARIFY]	—	ACTIVE NOT RECRUITING	2026-09	NCT06074510
Bayer	Radium-223 dichloride (Xofigo, BAY88-8223)	—	ACTIVE NOT RECRUITING	2025-11-21	NCT04597125
AstraZeneca	olaparib	Poly(ADP-Ribose) Polymerase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2024-10-22	NCT05457257
Johnson & Johnson	Apalutamide	Androgen Receptor	ACTIVE NOT RECRUITING	2023-06-01	NCT04108208
Blue Earth Diagnostics	fluciclovine (18F)	—	NOT YET RECRUITING	2027-12-31	NCT07569926
Blue Earth Diagnostics	flotufolastat (18F)	—	COMPLETED	2025-08-29	NCT06604442
Astellas Pharma Inc	Enzalutamide	Androgen Receptor Inhibitor [EPC]	COMPLETED	2024-02-20	NCT03641560
RECORDATI GROUP	Pasireotide	—	COMPLETED	2023-07-25	NCT01794793
Ferring Pharmaceuticals	Degarelix	—	COMPLETED	2020-05-15	NCT02726009
Astellas Pharma Inc	Enzalutamide	Androgen Receptor Inhibitor [EPC]	COMPLETED	2020-03-27	NCT02918968
Astellas Pharma Singapore Pte. Ltd.	Leuprolide	—	COMPLETED	2019-11-19	NCT03035032
Ipsen	Triptorelin 11.25 mg	—	COMPLETED	2019-09-09	NCT01753297
Sanofi	cabazitaxel XRP6258	—	COMPLETED	2019-03-27	NCT02485691
Zodiac Produtos Farmaceuticos S.A.	Leuprorelin Acetate (Eligard® 45 mg).	—	COMPLETED	2018-06-15	NCT05304169
Janssen Pharmaceutical K.K.	Abiraterone Acetate	CYP17	COMPLETED	2017-12-31	NCT02405858
Pfizer	Enzalutamide	Androgen Receptor Inhibitor [EPC]	COMPLETED	2016-11-15	NCT01995513
Astellas Pharma Europe B.V.	Enzalutamide	Androgen Receptor Inhibitor [EPC]	COMPLETED	2016-05-08	NCT02116582
Sanofi	CABAZITAXEL XRP6258	—	COMPLETED	2016-03	NCT02074137
Astellas Pharma Global Development, Inc.	Enzalutamide	Androgen Receptor Inhibitor [EPC]	COMPLETED	2016-02-01	NCT01977651
Sanofi	CABAZITAXEL XRP6258	—	COMPLETED	2016-02	NCT02441894
Axogen Corporation	—	—	COMPLETED	2015-04	NCT00953277
Sanofi	CABAZITAXEL (XRP6258)	—	COMPLETED	2014-01	NCT01649635
HanAll BioPharma Co., Ltd.	ELIGARD 22.5mg	—	COMPLETED	2013-05	NCT01511874
Watson Pharmaceuticals	Triptorelin pamoate	GnRH receptor	COMPLETED	2011-04	NCT01161563
AstraZeneca	Zoladex and Casodex	—	TERMINATED	2022-11-09	NCT03971110
Astellas Pharma Global Development, Inc.	Enzalutamide	Androgen Receptor Inhibitor [EPC]	TERMINATED	2017-03-15	NCT02441517
Astellas Pharma Europe Ltd.	Eligard	—	TERMINATED	2015-08	NCT01933022
Advanced Medical Diagnostics s.a.	—	—	TERMINATED	2014-07	NCT01950871
Ipsen	Decapeptyl® SR 22.5mg	—	TERMINATED	2014-02	NCT01673984

Showing 100 of 173 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Telix Pharmaceuticals (Innovations) Pty Limited	68Ga-PSMA-11	—	RECRUITING	2026-06	NCT07052214
Clarity Pharmaceuticals Ltd	64Cu-SAR-bisPSMA	—	RECRUITING	2026-09	NCT06056830
Curium US LLC	Copper Cu 64 PSMA I&T	—	RECRUITING	2026-09	NCT06235151
Pfizer	PF-06821497	—	RECRUITING	2026-12-02	NCT06629779
Jiangsu HengRui Medicine Co., Ltd.	Rezvilutamide Tablets	—	RECRUITING	2027-03	NCT07241416
ABX advanced biochemical compounds GmbH	[18F]PSMA-1007	—	RECRUITING	2027-03	NCT06122584
Bristol-Myers Squibb	BMS-986365	—	RECRUITING	2027-09-12	NCT06764485
Johnson & Johnson	Pasritamig	—	RECRUITING	2027-11-19	NCT07225946
Telix Pharmaceuticals (Innovations) Pty Limited	177Lu-TLX591	—	RECRUITING	2027-12	NCT06520345
Jiangsu HengRui Medicine Co., Ltd.	HRS-4357 injection	—	RECRUITING	2027-12	NCT07311694
AstraZeneca	Saruparib	—	RECRUITING	2028-01-11	NCT06120491
Novartis	AAA617	—	RECRUITING	2028-04-25	NCT05939414
Merck	Opevesostat	—	RECRUITING	2028-05-10	NCT06136650
Five Eleven Pharma, Inc.	—	—	RECRUITING	2028-06-01	NCT05381103
Merck	Ifinatamab deruxtecan	—	RECRUITING	2028-06-26	NCT06925737
Novartis	Investigators choice of SoC	—	RECRUITING	2028-06-27	NCT06780670
Merck	Opevesostat	—	RECRUITING	2028-08-02	NCT06136624
Pfizer	Mevrometostat	—	RECRUITING	2028-09-12	NCT07028853
Novartis	AAA817	—	RECRUITING	2028-09-29	NCT06855277
Amgen	Xaluritamig	—	RECRUITING	2030-01-07	NCT07213674
BioNTech SE	BNT324	—	RECRUITING	2031-02	NCT07365995
AstraZeneca	Saruparib	—	RECRUITING	2033-03-31	NCT06952803
HTA Co., Ltd.	Florastamin[18F] Injection	—	RECRUITING	2026-01-01	NCT06754085
Telix Pharmaceuticals (Innovations) Pty Limited	68Ga-PSMA-11	—	RECRUITING	2025-12-30	NCT05847348
Dongkook Pharmaceutical Co., Ltd.	DKF-MA102	—	RECRUITING	2025-05-20	NCT06490328
Aragon Pharmaceuticals, Inc.	Apalutamide	Androgen Receptor	ACTIVE NOT RECRUITING	2026-06-30	NCT02531516
Pfizer	PF-06821497	—	ACTIVE NOT RECRUITING	2026-07-13	NCT06551324
Johnson & Johnson	Apalutamide	Androgen Receptor	ACTIVE NOT RECRUITING	2026-10-12	NCT05884398
Johnson & Johnson	Apalutamide	Androgen Receptor	ACTIVE NOT RECRUITING	2026-12-01	NCT03767244
Clarity Pharmaceuticals Ltd	64Cu-SAR-bisPSMA	—	ACTIVE NOT RECRUITING	2026-12-31	NCT06970847
Jiangsu HengRui Medicine Co., Ltd.	Fuzuloparib , Abiraterone acetate and Prednisone	—	ACTIVE NOT RECRUITING	2026-12-31	NCT04691804
Bayer	Darolutamide (BAY1841788, Nubeqa)	—	ACTIVE NOT RECRUITING	2027-07-30	NCT05794906
Amgen	Xaluritamig	—	ACTIVE NOT RECRUITING	2029-01-02	NCT06691984
Janssen Pharmaceutica N.V., Belgium	LHRHa	—	ACTIVE NOT RECRUITING	2029-08-27	NCT04557059
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair	Abiraterone - Usual	—	ACTIVE NOT RECRUITING	2026-05-18	NCT03348670
AstraZeneca	capivasertib	AKT1/AKT2/AKT3	ACTIVE NOT RECRUITING	2026-03-04	NCT05348577
Pfizer	talazoparib plus enzalutamide	—	ACTIVE NOT RECRUITING	2026-02-18	NCT04821622
Novartis	177Lu-PSMA-617	—	ACTIVE NOT RECRUITING	2025-01-13	NCT04720157
Johnson & Johnson	Niraparib	—	ACTIVE NOT RECRUITING	2025-01-07	NCT04497844
AstraZeneca	Capivasertib	AKT1/AKT2/AKT3	ACTIVE NOT RECRUITING	2024-10-07	NCT04493853
Candel Therapeutics, Inc.	Aglatimagene besadenovec + valacyclovir	—	ACTIVE NOT RECRUITING	2024-08	NCT01436968
ITEL Telecomunicazioni Srl	Radiopharmaceutical 18F-JK-PSMA-7	—	ACTIVE NOT RECRUITING	2024-06	NCT05622162
Exelixis	Cabozantinib	AXL/FLT-3/KIT/MER/MET/RET/ROS1/TIE-2/TRKB/TYRO3/VEGFR-1/VEGFR-2/VEGFR-3	ACTIVE NOT RECRUITING	2024-04-19	NCT04446117
Eli Lilly	Abemaciclib	Kinase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2024-02-15	NCT05288166
AstraZeneca	olaparib	Poly(ADP-Ribose) Polymerase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2024-01-22	NCT05171816
Eli Lilly	Abemaciclib	Kinase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2024-01-02	NCT03706365
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company	[Lu-177]-PNT2002	—	ACTIVE NOT RECRUITING	2023-11-01	NCT04647526
Pfizer	Enzalutamide	Androgen Receptor Inhibitor [EPC]	ACTIVE NOT RECRUITING	2023-01-31	NCT02319837
Merck	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	ACTIVE NOT RECRUITING	2022-12-12	NCT03834493
Astellas Pharma China, Inc.	Enzalutamide	Androgen Receptor Inhibitor [EPC]	ACTIVE NOT RECRUITING	2022-11-18	NCT04076059
Novartis	177Lu-PSMA-617	—	ACTIVE NOT RECRUITING	2022-10-02	NCT04689828
AstraZeneca	olaparib	Poly(ADP-Ribose) Polymerase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2021-07-30	NCT03732820
Aragon Pharmaceuticals, Inc.	Apalutamide	Androgen Receptor	ACTIVE NOT RECRUITING	2020-09-07	NCT02489318
Aragon Pharmaceuticals, Inc.	Apalutamide	Androgen Receptor	ACTIVE NOT RECRUITING	2018-03-19	NCT02257736
Aragon Pharmaceuticals, Inc.	Apalutamide	Androgen Receptor	ACTIVE NOT RECRUITING	2017-05-19	NCT01946204
Qilu Pharmaceutical Co., Ltd.	QLG1080	—	NOT YET RECRUITING	2026-11	NCT06837896
Curium US LLC	Copper Cu 64 PSMA I&T	—	COMPLETED	2025-02-18	NCT06235099
Sumitomo Pharma America, Inc.	Relugolix	Gonadotropin Releasing Hormone Receptor Antagonist [EPC]	COMPLETED	2025-01-02	NCT05605964
Ipsen	Triptorelin pamoate (embonate) salt	—	COMPLETED	2024-08-20	NCT05590793
Ipsen	Triptorelin embonate 22.5 mg	—	COMPLETED	2024-07-08	NCT05458856
Bayer	Darolutamide (Nubeqa, BAY1841788)	—	COMPLETED	2024-06-07	NCT04736199
Changchun GeneScience Pharmaceutical Co., Ltd.	Leuprolide Injectable Emulsion (CAMCEVI®)	—	COMPLETED	2023-11-30	NCT06984159
Eurofarma Laboratorios S.A.	Inj. Goserelin (Test) Subcutaneously	—	COMPLETED	2023-11-30	NCT03936218
Novartis	[18F]CTT1057	—	COMPLETED	2023-11-24	NCT04838626
Novartis	[18F]CTT1057	—	COMPLETED	2023-11-23	NCT04838613
ABX advanced biochemical compounds GmbH	[18F]PSMA-1007	—	COMPLETED	2023-06-23	NCT04742361
Bristol-Myers Squibb	Nivolumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2023-06-01	NCT04100018
pharmaand GmbH	Rucaparib	—	COMPLETED	2023-03-08	NCT04676334
Merck	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2022-10-31	NCT04191096
Merck	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2022-10-31	NCT04934722
Tavanta Therapeutics	TAVT-45	—	COMPLETED	2022-10-20	NCT04887506
pharmaand GmbH	Rucaparib	—	COMPLETED	2022-08-25	NCT02975934
Merck	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2022-06-20	NCT03834506
Merck	Pembrolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2022-03-14	NCT03834519
Bayer	BAY1841788 / darolutamide (ODM-201)	—	COMPLETED	2021-10-25	NCT02799602
Blue Earth Diagnostics	rhPSMA-7.3 (18F) Injection	—	COMPLETED	2021-06-21	NCT04186819
Blue Earth Diagnostics	rhPSMA-7.3 (18F) Injection	—	COMPLETED	2021-04-28	NCT04186845
Johnson & Johnson	Abiraterone acetate	CYP17	COMPLETED	2021-04-22	NCT01517802
Luye Pharma Group Ltd.	LY01005 3.6 mg	—	COMPLETED	2021-03-09	NCT04563936
Endocyte	177Lu-PSMA-617	—	COMPLETED	2021-01-27	NCT03511664
AB Science	Masitinib	—	COMPLETED	2020-12-15	NCT03761225
ABX advanced biochemical compounds GmbH	F-18-PSMA-1007	—	COMPLETED	2020-10-30	NCT04102553
Astellas Pharma Europe Ltd.	Enzalutamide	Androgen Receptor Inhibitor [EPC]	COMPLETED	2020-04-30	NCT02288247
Roche	Ipatasertib	—	COMPLETED	2020-03-16	NCT03072238
SOTIO a.s.	DCVAC/PCa	—	COMPLETED	2020-01-28	NCT02111577
Myovant Sciences GmbH	Relugolix	Gonadotropin Releasing Hormone Receptor Antagonist [EPC]	COMPLETED	2019-10-25	NCT03085095
Progenics Pharmaceuticals, Inc.	18F-DCFPyL	—	COMPLETED	2019-08-29	NCT03739684
Roche	Atezolizumab	Programmed Death Receptor-1 Blocking Antibody [EPC]	COMPLETED	2019-06-24	NCT03016312
AstraZeneca	olaparib	Poly(ADP-Ribose) Polymerase Inhibitor [EPC]	COMPLETED	2019-06-04	NCT02987543
Foresee Pharmaceuticals Co., Ltd.	Leuprolide Mesylate	—	COMPLETED	2018-11-19	NCT03261999
Astellas Pharma Global Development, Inc.	Enzalutamide	Androgen Receptor Inhibitor [EPC]	COMPLETED	2018-10-14	NCT02677896
Bayer	Darolutamide (Nubeqa, BAY1841788)	—	COMPLETED	2018-09-03	NCT02200614
Amgen	Denosumab	RANK Ligand Inhibitor [EPC]	COMPLETED	2018-08-10	NCT01419717
Progenics Pharmaceuticals, Inc.	18F-DCFPyL Injection	—	COMPLETED	2018-07	NCT02981368
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Abiraterone Acetate	CYP17	COMPLETED	2018-03-14	NCT04056754
Bayer	Radium-223 dichloride (Xofigo, BAY88-8223)	—	COMPLETED	2018-02-15	NCT02043678
Molecular Insight Pharmaceuticals, Inc.	99mTc-MIP-1404 Injection	—	COMPLETED	2017-12-28	NCT02615067
Blue Earth Diagnostics	18F-fluciclovine PET CT	—	COMPLETED	2017-11-01	NCT02680041
Bavarian Nordic	PROSTVAC-V	—	COMPLETED	2017-09-25	NCT01322490
Bayer	Radium-223 dichloride (Xofigo, BAY88-8223)	—	COMPLETED	2017-09-25	NCT01810770

Showing 100 of 371 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Jiangsu HengRui Medicine Co., Ltd.	HRS-5041 tablets	—	RECRUITING	2026-06	NCT06568094
Portage Biotech	TT-10	—	RECRUITING	2026-06-01	NCT04969315
Novartis	AAA617	—	RECRUITING	2026-06-17	NCT06004661
Syntrix Biosystems, Inc.	SX-682	—	RECRUITING	2026-06-30	NCT06228053
Candel Therapeutics, Inc.	aglatimagene besadenovec + valacyclovir	—	RECRUITING	2026-08	NCT07332000
AtlasMedx, Incorporated	AMXI-5001:Dose Escalation Phase I	—	RECRUITING	2026-08	NCT04503265
PMV Pharmaceuticals, Inc	rezatapopt	—	RECRUITING	2026-08-15	NCT04585750
Blue Earth Therapeutics Ltd	Lutetium (177Lu) rhPSMA-10.1 Injection	—	RECRUITING	2026-08-27	NCT05413850
Clarity Pharmaceuticals Ltd	64Cu-SAR-bisPSMA	—	RECRUITING	2026-09	NCT04868604
AstraZeneca	AZD0754	—	RECRUITING	2026-11-24	NCT06267729
Zenith Epigenetics	ZEN003694	—	RECRUITING	2026-12	NCT04986423
858 Therapeutics, Inc.	ETX-19477	—	RECRUITING	2026-12	NCT06395519
MediLink Therapeutics (Suzhou) Co., Ltd.	YL201 for Injection	—	RECRUITING	2027-02	NCT06241846
Cellvax Therapeutics Inc	FK-PC101	—	RECRUITING	2027-02-02	NCT06636682
Halda Therapeutics OpCo, Inc.	HLD-0915	—	RECRUITING	2027-03	NCT06800313
Apollo Therapeutics Ltd	APL-5125	—	RECRUITING	2027-04	NCT06399757
Curacell Holding AB	CC-38	—	RECRUITING	2027-04	NCT07255664
Parabilis Medicines, Inc.	FOG-001	—	RECRUITING	2027-04-01	NCT05919264
SpectraCure AB	Verteporfin	Photoenhancer [EPC]	RECRUITING	2027-07-31	NCT03067051
Daiichi Sankyo	HER3-DXd	—	RECRUITING	2027-09-01	NCT06172478
ImmunoGenesis	Evofosfamide	—	RECRUITING	2027-10	NCT06782555
AstraZeneca	Datopotamab deruxtecan (Dato-DXd)	—	RECRUITING	2027-10-01	NCT05489211
Merck	Pembrolizumab 200 mg	—	RECRUITING	2027-10-22	NCT02861573
Filamon LTD	A novel hGIIA-Vimentin Inhibitor	—	RECRUITING	2027-10-26	NCT06926075
Jiangsu HengRui Medicine Co., Ltd.	SHR-4394	—	RECRUITING	2027-11	NCT07407283
Regeneron	REGN5678	—	RECRUITING	2027-11-15	NCT03972657
Radiopharm Theranostics, Ltd	177Lu-BetaBart	—	RECRUITING	2027-12	NCT07189871
Phanes Therapeutics	Peluntamig (PT217)	—	RECRUITING	2027-12	NCT05652686
SpectraCure AB	Verteporfin Injection	—	RECRUITING	2028-01	NCT06807359
Celcuity Inc	Gedatolisib	—	RECRUITING	2028-01	NCT06190899
Jacobio Pharmaceuticals Co., Ltd.	JAB-8263	—	RECRUITING	2028-01	NCT04686682
Roche	Inavolisib	Kinase Inhibitor [EPC]	RECRUITING	2028-03-31	NCT07287150
Kyntra Bio	FG-3246	—	RECRUITING	2028-03-31	NCT06842498
Syncromune, Inc.	SV-102	—	RECRUITING	2028-04-14	NCT06533644
Bayer	Darolutamide	Androgen Receptor/Progesterone Receptor	RECRUITING	2028-06-15	NCT07450599
Pathos AI, Inc.	Pocenbrodib	—	RECRUITING	2028-06-30	NCT06785636
Novartis	AMO959	—	RECRUITING	2028-07-10	NCT07226986
ModeX Therapeutics, An OPKO Health Company	MDX2001	—	RECRUITING	2028-08	NCT06239194
Tanabe Pharma America, Inc.	MT-4561	—	RECRUITING	2028-08	NCT06943521
Evopoint Biosciences Inc.	XNW5004	—	RECRUITING	2028-08	NCT06022757
Radiopharm Theranostics, Ltd	161Tb RAD402	—	RECRUITING	2028-11-30	NCT07259213
Jiangsu HengRui Medicine Co., Ltd.	HS-20093 for Injection	—	RECRUITING	2028-12	NCT07230106
Acerand Therapeutics (Shanghai) Limited	ACE-86225106 tablet	—	RECRUITING	2028-12-21	NCT06380660
Merck	Opevesostat	—	RECRUITING	2029-01-15	NCT06353386
AstraZeneca	AZD0516	—	RECRUITING	2029-01-18	NCT07181161
AstraZeneca	AZD9750	—	RECRUITING	2029-01-26	NCT07336446
AdvanCell Pty Limited	[²¹²Pb]Pb-ADVC001 (Phase 1b)	—	RECRUITING	2029-01-31	NCT05720130
AstraZeneca	AZD6621	—	RECRUITING	2029-03-29	NCT07192614
Arsenal Biosciences, Inc.	AB-3028	—	RECRUITING	2029-05	NCT07285694
Pfizer	PF-07248144	—	RECRUITING	2029-07-13	NCT04606446
Astellas Pharma Global Development, Inc.	enzalutamide	Androgen Receptor Inhibitor [EPC]	RECRUITING	2029-07-31	NCT02960022
MBrace Therapeutics	ADC	—	RECRUITING	2029-09-30	NCT07145255
Minghui Pharmaceutical (Hangzhou) Ltd	MHB048C for Injection	—	RECRUITING	2029-10	NCT07192120
Novartis	Tulmimetostat DL1 QD	—	RECRUITING	2029-11-09	NCT07206056
Novartis	Tulmimetostat	—	RECRUITING	2030-02-27	NCT04104776
Regeneron	REGN4336	—	RECRUITING	2030-03-28	NCT05125016
IDEAYA Biosciences	IDE574	—	RECRUITING	2030-03-30	NCT07540572
Novartis	GVV858	—	RECRUITING	2031-05-09	NCT07288359
Dendreon	Sipuleucel-T Injection	—	RECRUITING	2031-12-31	NCT06134232
Novartis	JSB462	—	RECRUITING	2032-03-29	NCT06991556
Astellas Pharma Global Development, Inc.	ASP5541	—	RECRUITING	2032-05-31	NCT07005154
Novartis	Tulmimetostat	—	RECRUITING	2032-08-02	NCT07190300
Evopoint Biosciences Inc.	XNW5004	—	RECRUITING	2026-05-13	NCT06702995
Bivision Pharmaceuticals, Inc.	Lutetium Lu 177 JH020002 Injection	—	RECRUITING	2026-05	NCT06139575
Shenzhen Ionova Life Sciences Co., Ltd.	INV-9956	—	RECRUITING	2026-04-17	NCT06609005
Hinova Pharmaceuticals Inc.	HP518 - Dose Escalation	—	RECRUITING	2026-03	NCT06155084
Convergent Therapeutics	In-111 rosopatamab tetraxetan	—	RECRUITING	2025-12	NCT06549465
RemeGen Co., Ltd.	Disitamab Vedotin Injection	—	RECRUITING	2025-12	NCT06227156
Sinotau Pharmaceutical Group	Phase I:[177Lu]Lu-XT033 Injection	—	RECRUITING	2025-12	NCT06081686
Jiangsu HengRui Medicine Co., Ltd.	HRS-1167 tablets	—	RECRUITING	2025-11-30	NCT06689163
Curasight	64Cu-DOTA-AE105	—	RECRUITING	2025-09-01	NCT06474806
Biozeus Biopharmaceutical S.A.	Tadalafil 5mg	—	RECRUITING	2024-12-31	NCT05558007
Hansoh BioMedical R&D Company	HS-20093	—	RECRUITING	2024-12-31	NCT06001255
OncoC4, Inc.	ONC-392 low	—	ACTIVE NOT RECRUITING	2026-06-30	NCT05682443
OncoC4, Inc.	ONC-392	—	ACTIVE NOT RECRUITING	2026-06-30	NCT04140526
Orion Corporation, Orion Pharma	ODM-208	—	ACTIVE NOT RECRUITING	2026-07-31	NCT03436485
Pfizer	PF-07220060	—	ACTIVE NOT RECRUITING	2026-09-23	NCT04557449
Novartis	AAA617	—	ACTIVE NOT RECRUITING	2026-10-15	NCT06894511
Novartis	225Ac-PSMA-R2	—	ACTIVE NOT RECRUITING	2026-11-19	NCT05983198
Debiopharm International SA	Debio 4228	—	ACTIVE NOT RECRUITING	2026-12	NCT06395753
Sapience Therapeutics	ST101	—	ACTIVE NOT RECRUITING	2026-12	NCT04478279
Novartis	AAA617	—	ACTIVE NOT RECRUITING	2026-12-23	NCT05849298
Fusion Pharmaceuticals Inc.	FPI-2265	—	ACTIVE NOT RECRUITING	2026-12-23	NCT06402331
Nuvation Bio Inc.	NUV-1511	—	ACTIVE NOT RECRUITING	2027-03	NCT06334432
Fusion Pharmaceuticals Inc.	FPI-2265	—	ACTIVE NOT RECRUITING	2027-05	NCT06909825
Novartis	ARV-766 Part A&B	—	ACTIVE NOT RECRUITING	2027-05-25	NCT05067140
AstraZeneca	AZD5305	—	ACTIVE NOT RECRUITING	2027-05-28	NCT04644068
Sensei Biotherapeutics, Inc.	SNS-101 (anti-VISTA)	—	ACTIVE NOT RECRUITING	2027-06	NCT05864144
AstraZeneca	AZD5305	—	ACTIVE NOT RECRUITING	2031-04-11	NCT05367440
R-Pharm International, LLC	RS-113, 160 mg	—	ACTIVE NOT RECRUITING	2026-05-14	NCT07553988
Monte Rosa Therapeutics, Inc	Oral MRT-2359	—	ACTIVE NOT RECRUITING	2026-05	NCT05546268
Xencor, Inc.	vudalimab	—	ACTIVE NOT RECRUITING	2025-10-15	NCT05032040
Norroy Bioscience Co., LTD	177Lu-NYM032 injection	—	ACTIVE NOT RECRUITING	2025-06-30	NCT06383052
Bayer	Darolutamide (BAY1841788, Nubeqa)	—	ACTIVE NOT RECRUITING	2025-05-30	NCT05059236
Fusion Pharmaceuticals Inc.	FPI-2265	—	ACTIVE NOT RECRUITING	2025-05-30	NCT05219500
Cellbion Co., Ltd.	Lu-177-DGUL	—	ACTIVE NOT RECRUITING	2024-12-31	NCT05547061
Novartis	[177Lu]Lu-PSMA-617	—	ACTIVE NOT RECRUITING	2024-12-02	NCT05658003
Health Ever Bio-Tech Co., Ltd.	MCS®	—	ACTIVE NOT RECRUITING	2024-12	NCT02042807
Candel Therapeutics, Inc.	aglatimagene besadenovec	—	ACTIVE NOT RECRUITING	2024-11	NCT02768363
Novartis	[177Lu]Lu-PSMA-617	—	ACTIVE NOT RECRUITING	2024-05-17	NCT05670106

Showing 100 of 294 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Full-Life Technologies GmbH	[225Ac]Ac-FL-020	—	RECRUITING	2026-06	NCT06492122
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd	SYN818	—	RECRUITING	2026-06-30	NCT06666270
AstraZeneca	Saruparib (AZD5305)	—	RECRUITING	2026-08-17	NCT05938270
Nurix Therapeutics, Inc.	NX-1607	—	RECRUITING	2026-08-31	NCT05107674
SURGE Therapeutics	STM-416p	—	RECRUITING	2026-09	NCT06450106
Angiex, Inc.	AGX101	—	RECRUITING	2026-09-06	NCT06440005
IDEAYA Biosciences	IDE-161	—	RECRUITING	2026-10	NCT05787587
Zumutor Biologics Inc.	ZM008	—	RECRUITING	2026-12	NCT06451497
Atridia Pty Ltd.	HRS-5041 Single dose of HRS-5041 orally administered	—	RECRUITING	2026-12-30	NCT06830850
Phrontline Biopharma	TJ101	—	RECRUITING	2026-12-30	NCT07181473
Tasly Pharmaceutical Group Co., Ltd	Treatment arm: TSL2109 capsules。Oral administration。	—	RECRUITING	2026-12-31	NCT07514065
Orano Med LLC	²¹²Pb-DOTAM-GRPR1	—	RECRUITING	2027-01	NCT05283330
Johnson & Johnson	Pasritamig	—	RECRUITING	2027-01-07	NCT07319871
Amgen	Xaluritamig	—	RECRUITING	2027-01-22	NCT06613100
Johnson & Johnson	JNJ-78278343	—	RECRUITING	2027-01-28	NCT07082920
ViroMissile, Inc.	IDOV-Immune (oncolytic vaccinia virus)	—	RECRUITING	2027-01-31	NCT06910657
Shanghai AbelZeta Ltd.	dnTGFβRII-armoured STEAP2-targeted autologous CAR T-Cell Injection	—	RECRUITING	2027-01-31	NCT07344311
Jiangsu HengRui Medicine Co., Ltd.	SHR4394	—	RECRUITING	2027-03	NCT06783829
Eli Lilly	LY4052031	—	RECRUITING	2027-05	NCT06465069
AbbVie	ABBV-969	—	RECRUITING	2027-05	NCT06318273
Olema Pharmaceuticals, Inc.	OP-3136	—	RECRUITING	2027-05-30	NCT06784193
Novartis	JSB462	—	RECRUITING	2027-06-18	NCT07174063
Johnson & Johnson	JNJ-78278343	—	RECRUITING	2027-06-21	NCT06095089
Roche	RO7656594	—	RECRUITING	2027-06-30	NCT05800665
Janux Therapeutics	JANX007	—	RECRUITING	2027-07	NCT05519449
Dren Bio	DR-0202	—	RECRUITING	2027-07	NCT06999187
IDEAYA Biosciences	IDE034	—	RECRUITING	2027-07-30	NCT07503808
Johnson & Johnson	Pasritamig	—	RECRUITING	2027-08-31	NCT05818683
K36 Therapeutics, Inc.	KTX-2001	—	RECRUITING	2027-09	NCT07103018
Vir Biotechnology, Inc.	VIR-5500	—	RECRUITING	2027-09-29	NCT05997615
Xadcera Biopharmaceutical (Suzhou) Co., Ltd.	DM002	—	RECRUITING	2027-10-08	NCT06751329
Aktis Oncology, Inc.	[225Ac]Ac-AKY-2519 (therapeutic)	—	RECRUITING	2027-12	NCT07581184
Clasp Therapeutics, Inc.	CLSP-1025	—	RECRUITING	2027-12	NCT06778863
Oscotec Inc.	OCT-598	—	RECRUITING	2027-12	NCT07358806
Hansoh BioMedical R&D Company	HS-20093	—	RECRUITING	2027-12	NCT07115446
TechnoGenesys, Inc.	(R)-9bMS	—	RECRUITING	2027-12-30	NCT06705686
Nammi Therapeutics Inc	QXL138AM Injection every 2 weeks by IV Infusion	—	RECRUITING	2027-12-31	NCT06582017
SystImmune Inc.	BL-M14D1	—	RECRUITING	2027-12-31	NCT07080242
Amgen	Xaluritamig	—	RECRUITING	2028-01-30	NCT07493512
Daiichi Sankyo	Valemetostat	—	RECRUITING	2028-01-31	NCT07244341
Acerand Therapeutics (Hong Kong) Limited	ACE-232 tablets	—	RECRUITING	2028-03-01	NCT06801236
Daiichi Sankyo	DS9051b	—	RECRUITING	2028-03-01	NCT07189403
Amgen	Xaluritamig	—	RECRUITING	2028-03-27	NCT07140900
BeiGene	BG-68501	—	RECRUITING	2028-04	NCT06257264
Pfizer	Mervometostat (PF-06821497)	—	RECRUITING	2028-04-20	NCT03460977
Janux Therapeutics	JANX014	—	RECRUITING	2028-05	NCT07545811
Novartis	AAA617	—	RECRUITING	2028-11-24	NCT06531499
Bayer	225Ac-PSMA-Trillium (BAY3563254)	—	RECRUITING	2028-11-26	NCT06217822
Astellas Pharma Global Development, Inc.	ASP5541	—	RECRUITING	2028-12-31	NCT07339267
Deciphera Pharmaceuticals, LLC	DCC-2812	—	RECRUITING	2029-02	NCT06966024
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.	EXS74539	—	RECRUITING	2029-03	NCT07517198
AstraZeneca	AZD2287	—	RECRUITING	2029-04-16	NCT06879041
Astellas Pharma Global Development, Inc.	PRL-02 injection	—	RECRUITING	2029-05-31	NCT04729114
Bristol-Myers Squibb	BMS-986460	—	RECRUITING	2029-08-24	NCT06067841
Amgen	AMG 509	—	RECRUITING	2030-03-22	NCT04221542
Hangzhou DAC Biotechnology Co., Ltd.	DXC008	—	RECRUITING	2030-04	NCT06926283
Novartis	INR731	—	RECRUITING	2030-06-03	NCT07570979
Exelixis	Zanzalintinib	—	RECRUITING	2030-06-28	NCT05176483
Hangzhou DAC Biotechnology Co., Ltd.	DXC014	—	RECRUITING	2030-10-20	NCT07177937
Novartis	225Ac-ETN029	—	RECRUITING	2031-08-29	NCT07006727
Jiangsu Hansoh Pharmaceutical Co., Ltd.	HS-10502 + NHA	—	RECRUITING	2026-05-07	NCT06769425
Sinotau Pharmaceutical Group	Flotufolastat F-18 Injection	—	RECRUITING	2025-12-31	NCT07149831
Nova Therapeutics LLC	CART-PSMA cells	—	RECRUITING	2025-12-01	NCT05656573
ORIC Pharmaceuticals	ORIC-944	—	RECRUITING	2025-12	NCT05413421
Oxford Vacmedix UK Ltd.	OVM-200	—	RECRUITING	2025-11-30	NCT05104515
Jiangsu HengRui Medicine Co., Ltd.	HRS-5041	—	RECRUITING	2025-08-31	NCT05942001
Epigenetix, Inc.	EP31670	—	RECRUITING	2025-05	NCT05488548
Novartis	[68Ga]Ga-PSMA-11	—	ACTIVE NOT RECRUITING	2026-08-24	NCT06379217
Exelixis	XL092	—	ACTIVE NOT RECRUITING	2026-08-31	NCT03845166
Amgen	Xaluritamig	—	ACTIVE NOT RECRUITING	2026-10-08	NCT06555796
Johnson & Johnson	JNJ-69086420	—	ACTIVE NOT RECRUITING	2026-12-08	NCT04644770
Johnson & Johnson	ARX517	—	ACTIVE NOT RECRUITING	2026-12-31	NCT04662580
Endocyte	—	—	ACTIVE NOT RECRUITING	2027-01-01	NCT04597411
Johnson & Johnson	JNJ-78278343	—	ACTIVE NOT RECRUITING	2027-02-10	NCT04898634
Eli Lilly	LY4101174	—	ACTIVE NOT RECRUITING	2027-03	NCT06238479
NeoTX Therapeutics Ltd.	—	—	ACTIVE NOT RECRUITING	2027-03-01	NCT03983954
MOMA Therapeutics	MOMA-313	—	ACTIVE NOT RECRUITING	2027-05-31	NCT06545942
Bayer	BAY3546828	—	ACTIVE NOT RECRUITING	2027-06-08	NCT06052306
Eli Lilly	[Ac-225]-PSMA-62 (mCRPC)	—	ACTIVE NOT RECRUITING	2027-09	NCT06229366
ARTBIO Inc.	AB001	—	ACTIVE NOT RECRUITING	2027-11-03	NCT07214961
Atavistik Bio, Inc	ATV-1601	—	ACTIVE NOT RECRUITING	2028-08-31	NCT07038369
C Ray Therapeutics	Intravenous (IV) single dose	—	ACTIVE NOT RECRUITING	2026-04-01	NCT07236112
Theratechnologies	TH1902	—	ACTIVE NOT RECRUITING	2025-12	NCT04706962
NGM Biopharmaceuticals, Inc	NGM831	—	ACTIVE NOT RECRUITING	2025-07	NCT05215574
Agenus Inc.	Botensilimab	—	ACTIVE NOT RECRUITING	2025-01-13	NCT03860272
Exelixis	cabozantinib	AXL/FLT-3/KIT/MER/MET/RET/ROS1/TIE-2/TRKB/TYRO3/VEGFR-1/VEGFR-2/VEGFR-3	ACTIVE NOT RECRUITING	2023-02-21	NCT03170960
Johnson & Johnson	Niraparib	—	ACTIVE NOT RECRUITING	2021-10-15	NCT04577833
Johnson & Johnson	Apalutamide	Androgen Receptor	ACTIVE NOT RECRUITING	2019-07-09	NCT03523442
Aragon Pharmaceuticals, Inc.	JNJ 56021927	—	ACTIVE NOT RECRUITING	2016-11-07	NCT02592317
Aragon Pharmaceuticals, Inc.	Abiraterone Acetate	CYP17	ACTIVE NOT RECRUITING	2016-06-27	NCT02123758
Danatlas Pharmaceuticals Co., Ltd	DAT-2645 tablet	—	NOT YET RECRUITING	2026-11-01	NCT06614751
IntoCell, Inc	ITC-6146RO	—	NOT YET RECRUITING	2027-06-30	NCT07423117
Philogen S.p.A.	[68Ga]Ga-OncoACP3	—	NOT YET RECRUITING	2027-12	NCT07600554
Moonlight Bio, Inc	ML261	—	NOT YET RECRUITING	2028-03	NCT07488923
Jiangsu HengRui Medicine Co., Ltd.	dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets	—	NOT YET RECRUITING	2028-12	NCT06099990
Cellbion Co., Ltd.	Lutetium (177Lu) DGUL	—	NOT YET RECRUITING	2029-04	NCT07244393
Regeneron	—	—	NOT YET RECRUITING	2029-12-13	NCT07543055
Gan & Lee Pharmaceuticals.	GLR2037	—	NOT YET RECRUITING	2031-10-30	NCT07468396
Geode Therapeutics Inc.	GT-220F capsule	—	NOT YET RECRUITING	2025-12	NCT06866795
Johnson & Johnson	JNJ-75229414	—	COMPLETED	2026-03-11	NCT05022849

Precision Medicine Biomarkers

All biomarkers →

Biomarkers used for patient selection in Prostate Cancer

ER (Estrogen Receptor) (27) AR (Androgen Receptor) (7) PR (Progesterone Receptor) (5)

Novel Drugs by Company (New molecular entities)

Pfizer 1 drug

Novartis 1 drug

Bayer 1 drug

TERSERA 1 drug

SAMSUNG BIOEPIS CO LTD 1 drug

PHARMAAND 1 drug

PROGENICS PHARMS INC 1 drug

VERITY 1 drug

SHANGHAI HENLIUS BIOTECH 1 drug

BLUE EARTH 1 drug

FLOTUFOLASTAT F-18 GALLIUM

NDA 2023

+3 more companies

Reformulations (15 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.